Skip to main content
SpringerLink
Log in

Alprostadil [NexMed] received a non-approvable letter from the US FDA

  • Media release
  • Published:
Inpharma Weekly

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alprostadil [NexMed] received a non-approvable letter from the US FDA. Inpharma Wkly. 1649, 21 (2008). https://doi.org/10.2165/00128413-200816490-00063

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-200816490-00063

Keywords

Search

Navigation